Does having a Canadian DIN mean a drug is covered by a provincial health plan?

No. A DIN means Health Canada has authorized the drug for sale. Coverage is a separate decision made by each province, territory, or private insurer, and it depends heavily on the indication written on the prescription. All eight DIN-holding brands on this page can be sold in a Canadian pharmacy; several of them cannot be claimed on most public drug plans regardless.

Why is Wegovy authorized in Canada but not covered by any of the four provinces checked here?

Authorization and coverage are different processes. Wegovy has a Canadian DIN and can be legally sold and dispensed. Coverage is a funding decision each provincial plan makes separately, and as of this writing none of Ontario, Quebec, BC or Alberta fund it for weight management, even though Canada's Drug Agency recommended a conditional coverage pathway in July 2025.

If I have diabetes and obesity, does that change which brand gets covered?

It can, but through the prescription's stated indication rather than through the person's full history. A prescriber writing for type 2 diabetes has a coverage pathway available through the diabetes-indicated brands (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity), subject to each plan's clinical criteria. Writing the identical molecule under an obesity-indicated brand for weight loss (Wegovy, Zepbound, Saxenda) generally exits public coverage even in the same patient.

GLP-1 Access in Canada: DINs and Coverage

What this page establishes

Ozempic (semaglutide) holds active Canadian DINs, including 02471469 and 02523930, market authorization holder Novo Nordisk Canada Inc.
Wegovy (semaglutide) holds active Canadian DINs, including 02522551 and 02528541 (the 2.4 mg dose), market authorization holder Novo Nordisk Canada Inc.
Rybelsus (oral semaglutide) holds active Canadian DINs, including 02497581, market authorization holder Novo Nordisk Canada Inc.
Mounjaro (tirzepatide) holds active Canadian DINs, including 02532891 and the Mounjaro KwikPen line, market authorization holder Eli Lilly Canada Inc.

Quick answers

Does having a Canadian DIN mean a drug is covered by a provincial health plan?
No. A DIN means Health Canada has authorized the drug for sale. Coverage is a separate decision made by each province, territory, or private insurer, and it depends heavily on the indication written on the prescription.
Read the full answer
All eight DIN-holding brands on this page can be sold in a Canadian pharmacy; several of them cannot be claimed on most public drug plans regardless.
Why is Wegovy authorized in Canada but not covered by any of the four provinces checked here?
Authorization and coverage are different processes. Wegovy has a Canadian DIN and can be legally sold and dispensed.
Read the full answer
Coverage is a funding decision each provincial plan makes separately, and as of this writing none of Ontario, Quebec, BC or Alberta fund it for weight management, even though Canada's Drug Agency recommended a conditional coverage pathway in July 2025.
If I have diabetes and obesity, does that change which brand gets covered?
It can, but through the prescription's stated indication rather than through the person's full history.
Read the full answer
A prescriber writing for type 2 diabetes has a coverage pathway available through the diabetes-indicated brands (Ozempic, Rybelsus, Mounjaro, Victoza, Trulicity), subject to each plan's clinical criteria. Writing the identical molecule under an obesity-indicated brand for weight loss (Wegovy, Zepbound, Saxenda) generally exits public coverage even in the same patient.

In Canada, a drug needs a Health Canada Notice of Compliance and a Drug Identification Number (DIN) before a pharmacy can dispense it. Getting a DIN says nothing about who pays for it. That second question runs through 13 separate provincial and territorial drug plans plus whatever an employer's private plan does, and the answer changes depending on whether the prescription is written for type 2 diabetes or for obesity, even when the drug in the pen is identical.

Which of the nine brands actually hold a Canadian DIN

Eight of the nine brands sold or discussed in the US market are authorized for sale in Canada, each with at least one active DIN in Health Canada's Drug Product Database: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity.

Foundayo has no Canadian DIN as of this writing. It does not appear in the Drug Product Database under that brand name, which means it is not authorized for sale in Canada. That is a direct database result, not an inference from silence elsewhere.

A DIN is issued per strength and delivery device, not once per brand, so a brand can carry several. Zepbound's Canadian authorization is recent: its DINs were last updated in the database on 2026-08-06, consistent with a brand that has only recently reached the Canadian market.

Market authorization holders Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are held by Novo Nordisk Canada Inc. Mounjaro, Zepbound and Trulicity are held by Eli Lilly Canada Inc. These are the companies of record in the DPD, not a claim about where the drug is manufactured.

The licence split that decides who gets covered

Health Canada authorizes these drugs against specific indications, and Canadian public payers follow the indication on the prescription, not the molecule in the pen. Ozempic, Rybelsus, Mounjaro, Victoza and Trulicity are authorized and marketed for type 2 diabetes. Wegovy, Zepbound and Saxenda are authorized and marketed for chronic weight management.

That split is the single biggest determinant of coverage in this country. Every public formulary reviewed for this page pays for the diabetes-indicated brands, under conditions, and none of them pays for the obesity-indicated brands for weight management as a matter of routine policy.

The practical effect: a prescriber who writes semaglutide for someone with obesity but no diabetes is choosing a brand (Wegovy) that is categorically excluded from public coverage in every province checked here, regardless of how sick the drug might otherwise make that person eligible to be.

Public coverage: four provinces, four different answers

Ontario lists Ozempic as a Limited Use benefit under the Ontario Drug Benefit Formulary (LU code 474), reimbursed for type 2 diabetes with inadequate glycemic control on metformin. Wegovy is not on the ODB formulary and weight-management use is not covered.

Quebec's RAMQ reimburses semaglutide (Ozempic, and Rybelsus) as a médicament d'exception for type 2 diabetes, with dosing conditions attached to the authorization. RAMQ does not cover Wegovy for weight management; someone prescribed it for obesity pays out of pocket.

British Columbia covers semaglutide through Special Authority, limited to type 2 diabetes after an inadequate response to a trial of metformin, and currently caps reimbursed dosing at 1 mg weekly (the 2 mg diabetes dose was under review for reimbursement at the time of writing). BC PharmaCare does not cover Wegovy for weight management.

Alberta's public drug plan covers Ozempic under Special Authorization for type 2 diabetes. Wegovy, Zepbound and Saxenda sit outside the Alberta Drug Benefit List entirely and are self-pay or private-insurance only.

The rest of the provinces and territories vary, and this page does not claim to have checked all thirteen. The shape repeats everywhere it has been checked: diabetes-indicated brands get a coverage pathway with clinical criteria attached, obesity-indicated brands do not.

CDA-AMC recommended a path for obesity coverage, conditionally Canada's Drug Agency (CDA-AMC, formerly CADTH) issued a conditional reimbursement recommendation for Wegovy in chronic weight management in July 2025: reimburse it for adults with a BMI of 27 kg/m2 or higher who also have established cardiovascular disease, provided the patient maintains a reduced-calorie diet and increased physical activity, shows at least a 5% reduction in BMI or body weight after the first year, and provided the price is reduced from the public list price. A CDA-AMC recommendation is advice to provincial plans, not funding. None of the four provinces reviewed here had implemented it as public coverage at the time of writing.

Private insurance covers most working-age Canadians, but weight-loss use is a coin flip

Most working-age Canadians get drug coverage through an employer plan rather than the provincial formulary, and private-plan policy on these drugs has been moving in one direction. Employer survey data reported in the Canadian benefits trade press shows the share of employers covering GLP-1s for diabetes only falling from 66% in 2024 to 56% in 2025 to 51% in 2026, while the share covering both diabetes and weight loss rose from 17% to 31% to 37% over the same period.

That means as of 2026 a slim majority of surveyed employer plans still exclude weight-loss use, and coverage that does exist typically requires prior authorization, a documented BMI threshold, and evidence of an accompanying lifestyle program. It is not automatic even where a plan technically covers it.

What it actually costs without coverage

Manufacturers do not publish a single retail price for Canada, and pharmacy pricing varies by province and by pharmacy. This page did not find a primary regulatory source (a PMPRB filing or a government price list) giving a current, citable retail figure, so the numbers below should be read as an approximate range compiled from multiple pharmacy-price-comparison sources rather than an authoritative price.

With that caveat: brand-name semaglutide for diabetes (Ozempic) has been reported in the roughly $260 to $290 CAD per month range without coverage, and Wegovy at the weight-management dose in the roughly $430 to $570 CAD per month range. Health Canada approved the first generic semaglutide injections (referencing Ozempic) from Dr. Reddy's and Apotex in spring 2026, and early reports put a generic cash price meaningfully below the brand, though this page has not independently verified a specific figure against a primary source.

The cross-border question

Canadian list prices for these drugs are often lower than US cash prices, and that gap has driven real cross-border demand: some American residents have sought prescriptions and product through Canadian pharmacies and Canada-licensed prescribers. This has already caused a documented supply problem inside Canada. In early 2023, British Columbia's health ministry reported that a large share of Ozempic prescriptions dispensed in the province in a short window went to American residents, contributing to a domestic shortage for BC patients with diabetes. Nova Scotia's physician regulator subsequently suspended the licence of a Nova-Scotia-registered doctor tied to roughly 17,000 semaglutide prescriptions written for out-of-province and out-of-country patients over a few months, and Ozempic prescriptions to Americans in BC reportedly dropped sharply afterward.

This is a live regulatory and supply question, not a settled one, and it sits on both sides of the border: Health Canada's mandate is domestic drug supply, and the FDA's personal-importation guidance for US buyers is enforcement discretion, not a legal right of import. Provinces have already shown they will act, including at the level of an individual prescriber's licence, when cross-border volume threatens supply for Canadian patients.

The evidence, one row per claim

Claim	Tier	Source
Ozempic (semaglutide) holds active Canadian DINs, including 02471469 and 02523930, market authorization holder Novo Nordisk Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Wegovy (semaglutide) holds active Canadian DINs, including 02522551 and 02528541 (the 2.4 mg dose), market authorization holder Novo Nordisk Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Rybelsus (oral semaglutide) holds active Canadian DINs, including 02497581, market authorization holder Novo Nordisk Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Mounjaro (tirzepatide) holds active Canadian DINs, including 02532891 and the Mounjaro KwikPen line, market authorization holder Eli Lilly Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Zepbound (tirzepatide) holds active Canadian DINs, including 02557509, market authorization holder Eli Lilly Canada Inc.; entries were last updated 2026-08-06, consistent with a recent Canadian launch.	established	Health Canada Drug Product Database (DPD) API
Saxenda (liraglutide) holds an active Canadian DIN, 02437899, market authorization holder Novo Nordisk Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Victoza (liraglutide) holds an active Canadian DIN, 02351064, market authorization holder Novo Nordisk Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Trulicity (dulaglutide) holds active Canadian DINs, including 02448572 and 02530163, market authorization holder Eli Lilly Canada Inc.	established	Health Canada Drug Product Database (DPD) API
Foundayo returns zero results in the Health Canada Drug Product Database and holds no Canadian DIN; it is not authorized for sale in Canada.	established	Health Canada Drug Product Database (DPD) API
Ontario lists Ozempic as a Limited Use benefit under the Ontario Drug Benefit Formulary, LU code 474, for type 2 diabetes with inadequate glycemic control on metformin; Wegovy is not on the ODB formulary.	established	Ontario Drug Benefit Formulary, Ministry of Health
RAMQ reimburses semaglutide (Ozempic) as a médicament d'exception for type 2 diabetes with dosing conditions attached, and does not cover Wegovy for weight management.	established	Régie de l'assurance maladie du Québec (RAMQ)
BC PharmaCare covers semaglutide through Special Authority only for type 2 diabetes after an inadequate response to a trial of metformin, currently capped at a 1 mg weekly dose; it does not cover Wegovy for weight management.	established	BC PharmaCare, Province of British Columbia
CDA-AMC (Canada's Drug Agency) issued a conditional reimbursement recommendation for Wegovy in chronic weight management in July 2025, restricted to adults with BMI ≥27 kg/m2 and established cardiovascular disease, contingent on lifestyle measures, a 5% weight/BMI reduction after year one, and a reduced price.	established	CDA-AMC (Canada's Drug Agency) Reimbursement Recommendation, Semaglutide (Wegovy), SR0841
Among Canadian employers surveyed, the share covering GLP-1 drugs for diabetes only fell from 66% (2024) to 56% (2025) to 51% (2026), while the share covering both diabetes and weight loss rose from 17% to 31% to 37% over the same period.	established	Benefits Canada, employer GLP-1 coverage survey reporting
Out-of-pocket cash pricing for these drugs in Canada (roughly $260-290 CAD/month for Ozempic, $430-570 CAD/month for Wegovy) is drawn from pharmacy-comparison sources, not a manufacturer list price or a PMPRB filing, and should be treated as approximate.	weak evidence	No primary Canadian retail-price source located; figure is a compiled estimate, cross-referenced against the CDA-AMC recommendation's stated annual treatment cost (~$5,066)
In early 2023, BC health authorities reported a large share of Ozempic prescriptions dispensed in the province went to American residents, contributing to a domestic supply shortage; Nova Scotia's physician regulator subsequently suspended a Nova-Scotia-licensed doctor tied to roughly 17,000 semaglutide prescriptions written mostly for out-of-province and US patients.	established	CBC News reporting on the Nova Scotia College of Physicians and Surgeons suspension

Questions people ask

Is it legal for a Canadian pharmacy to sell these drugs to an American customer?

This page describes the situation rather than advising on it. Cross-border sales have happened, have caused a documented Canadian supply shortage in at least one case, and have led a provincial physician regulator to suspend a doctor's licence over prescribing volume. Neither Health Canada's mandate nor US FDA import guidance treats this as a straightforward or risk-free transaction for either side.

Will private insurance in Canada cover a GLP-1 drug for weight loss?

It depends entirely on the employer's plan design. Survey data shows a growing but still-minority share of Canadian employer plans covering weight-loss use as of 2026, usually gated behind prior authorization, a BMI threshold, and evidence of a lifestyle program. A plan covering the diabetes indication does not automatically cover the obesity one.

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 16 sourced claims below the fold, each with the document it came from.

Sources consulted: Health Canada Drug Product Database, Ontario Drug Benefit Formulary, Régie de l'assurance maladie du Québec, BC PharmaCare, CDA-AMC and 3 more.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.

GLP-1 Access in Canada: DINs, Provincial Coverage and What It Actually Costs